Clinical Study

Sym021-02- An Exploratory, Open-Label, Multicenter Phase 1B Trial To Evaluate Safety And Efficacy Of Sym021 (Anti-Pd-1) In Combination With Either Sym022 (Anti-Lag-3) Or Sym023 (Anti-Tim-3) In Patients With Advanced Solid Tumor Malignancies

Posted Date: May 6, 2021

  • Investigator: Davendra Sohal
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The main purpose of this study is to evaluate safety and efficacy in participant with small cell lung cancer, urothelial cancer and bladder cancer who have developed resistance to prior anti-PD1 or anti-PD-L1 therapy and in patient with cholangiocarcinoma who have received at least 1 line of standard of care therapy and have progressed on it.


Documented (Histologically Or Cytologically Proven) Unresectable, Locally Advanced, Or Metastatic Small Cell Lung Cancer, Urothelial Cancer, Endometrial Cancer, Or Cholangiocarcinoma, Ecog Ps Of 0 Or 1, Life Expectancy Of =3 Months, No Serious/Active/Uncontrolled Infection Or Medical Condition That May Interfere With Patients Safety Or Ability To Adhere To Study Treatment, No Central Nervous System (Cns) Malignancies, No Known Or Suspected Hypersensitivity To Any Of The Excipients Of Formulated Study Drug


Lung Cancer, Urothelial Cancer, Bladder Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.